Prevention of UVB-induced skin cancer using sulforaphane: roles of AP-1 and Nrf2.
使用萝卜硫素预防 UVB 诱发的皮肤癌:AP-1 和 Nrf2 的作用。
基本信息
- 批准号:7588222
- 负责人:
- 金额:$ 11.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-29 至 2013-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingActinic keratosisAcuteAffectAmerican Association of Cancer ResearchAnimalsArizonaBioethicsBiological MarkersBiometryCancer BiologyCancer CenterCancer ModelCell NucleusChemicalsChemopreventionChemopreventive AgentChromatinChronicClinical ResearchClinical TrialsCreamCysteineDNA BindingDNA Binding DomainDailyDataDevelopment PlansDoseDouble-Blind MethodDrug FormulationsEpidermisExposure toFamily memberForearmGenotypeGoalsHistopathologyHumanIncidenceInstitutesIsothiocyanatesK-Series Research Career ProgramsKnock-outKnockout MiceLightLinkMalignant NeoplasmsMalignant Squamous Cell NeoplasmMeasurementMentorsMethodologyModelingMolecularMusMutateMutationNAD(P)H dehydrogenase (quinone) 1, humanNQO1 geneNuclearOxidantsOxidation-ReductionPatientsPhasePhenotypePlacebo ControlPlacebosPreventionPrevention programProgram Research Project GrantsProliferation MarkerProteinsPunch BiopsyRandomizedRateReference StandardsRegulationRelative (related person)Research PersonnelRiskRoleSafetySamplingScientistSkinSkin CancerSkin CarcinogenesisSkin CarcinomaSkin NeoplasmsSquamous CellStaining methodStainsStatistical DistributionsSulforaphaneTestingThinkingTitleToxic effectTrainingTransactivationTranscription Factor AP-1Transgenic MiceTumor BurdenUVB inducedUltraviolet B RadiationWorkactivating transcription factoranticancer researchcancer diagnosiscancer preventioncarcinogenesiscareercruciferous vegetableinterestkeratinocytemutantoxidative DNA damageplanetary Atmospherepreventprogramsresponsestemsymposiumtooltranscription factortreatment durationtumorvolunteer
项目摘要
DESCRIPTION (provided by applicant): Non-melanoma skin cancer (NMSC) rates are rising due to factors such as increased UVB light penetrating our atmosphere. Skin cancer, the majority of which is NMSC, accounts for nearly 40% of all diagnosed cancers in the U.S. It is my goal as a scientist to find new, applicable and affordable topical compounds which will be used to reduce the incidence of NMSC in humans. A K07 Career Development Award (CDA) is the most effective means for me to begin to accomplish these objectives and become a productive top-level cancer biologist. To accomplish this goal, I must become well-trained in cancer biology and clinical trial methodology. As part of my career development plan, I have assembled a team of outstanding mentors in skin cancer research, mouse studies, drug formulation, and clinical trials. I will have regular interactions with my mentors and will receive didactic training in subjects such as clinical trial management, bioethics, and biostatistics. I will attend AACR conferences, meetings for the Skin Cancer Program Project Grant and seminars in Cancer Prevention and Control. The Arizona Cancer Center and the Skin Cancer Institute provide me with unique and valuable tools for furthering my training and accomplishing my goals. Scientifically, this CDA will help me to examine the roles of AP-1 and Nrf2 in the mechanism of action of the chemopreventive compound sulforaphane (SF) in UVB-treated skin. SF is an isothiocyanate found in cruciferous vegetables, and inhibits carcinogenesis in several models, possibly due to induction of the transcription factor Nf E2-related factor 2 (Nrf2). Additionally, SF blocks the activity and DNA-binding ability of the activator protein-1 (AP-1) transcription factor, a key component in UVB-induced skin carcinogenesis. We hypothesize that SF inhibits DVB-induced skin carcinogenesis and will reduce the risk of squamous cell carcinogenesis in patients with sun-damaged skin through a dual mechanism of action: Nrf2 activation leading to reduced oxidative DNA damage, and AP-1 inhibition through direct redox modulation. To test this hypothesis we will 1) test whether the inhibitory effect of SF on AP-1 transactivation and skin carcinogenesis is due to chemical interactions with the DNA binding domain of cFos and/or cJun; 2) test the influence of SF- induced Nrf2 on-protection against acute UVB-induced mouse skin damage and chronic UVB-induced NMSC; 3) test the safety and efficacy of topical purified F in humans (a Phase l/lla clinical trial).
描述(由申请人提供):非黑色素瘤皮肤癌(NMSC)的发病率正在上升,这是由于穿透大气的UVB光增加等因素造成的。皮肤癌,其中大部分是NMSC,占美国所有诊断癌症的近40%。作为一名科学家,我的目标是找到新的,适用的和负担得起的局部化合物,用于减少人类NMSC的发病率。K07职业发展奖(CDA)是我开始实现这些目标,成为一名富有成效的顶级癌症生物学家的最有效手段。为了实现这一目标,我必须在癌症生物学和临床试验方法学方面接受良好的训练。作为我职业发展计划的一部分,我在皮肤癌研究、小鼠研究、药物配方和临床试验方面组建了一支优秀的导师团队。我将定期与导师互动,并接受临床试验管理、生物伦理学和生物统计学等学科的教学培训。我将参加AACR会议,皮肤癌计划项目拨款会议和癌症预防与控制研讨会。亚利桑那癌症中心和皮肤癌研究所为我提供了独特而有价值的工具,以促进我的培训和实现我的目标。科学地说,这个CDA将帮助我检查AP-1和Nrf2在化学预防化合物萝卜硫素(SF)在uvb处理过的皮肤中的作用机制。SF是十字花科蔬菜中发现的一种异硫氰酸盐,在几种模型中抑制致癌作用,可能是由于诱导转录因子Nf e2相关因子2 (Nrf2)。此外,SF阻断激活蛋白1 (AP-1)转录因子的活性和dna结合能力,AP-1转录因子是uvb诱导皮肤癌发生的关键成分。我们假设SF抑制dvb诱导的皮肤癌变,并通过双重作用机制降低晒伤皮肤患者的鳞状细胞癌变风险:Nrf2激活导致氧化DNA损伤减少,AP-1通过直接氧化还原调节抑制。为了验证这一假设,我们将1)测试SF对AP-1转激活和皮肤癌变的抑制作用是否由于与cFos和/或cJun的DNA结合域的化学相互作用;2)检测SF诱导的Nrf2对急性uvb诱导的小鼠皮肤损伤和慢性uvb诱导的NMSC的保护作用;3)测试局部纯化F在人体内的安全性和有效性(i / la期临床试验)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sally E Dickinson其他文献
Sally E Dickinson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sally E Dickinson', 18)}}的其他基金
Prevention of UVB-induced skin cancer using sulforaphane: roles of AP-1 and Nrf2.
使用萝卜硫素预防 UVB 诱发的皮肤癌:AP-1 和 Nrf2 的作用。
- 批准号:
7920527 - 财政年份:2009
- 资助金额:
$ 11.08万 - 项目类别:
Prevention of UVB-induced skin cancer using sulforaphane: roles of AP-1 and Nrf2.
使用萝卜硫素预防 UVB 诱发的皮肤癌:AP-1 和 Nrf2 的作用。
- 批准号:
8320947 - 财政年份:2008
- 资助金额:
$ 11.08万 - 项目类别:
Prevention of UVB-induced skin cancer using sulforaphane: roles of AP-1 and Nrf2.
使用萝卜硫素预防 UVB 诱发的皮肤癌:AP-1 和 Nrf2 的作用。
- 批准号:
8130646 - 财政年份:2008
- 资助金额:
$ 11.08万 - 项目类别:
Prevention of UVB-induced skin cancer using sulforaphane: roles of AP-1 and Nrf2.
使用萝卜硫素预防 UVB 诱发的皮肤癌:AP-1 和 Nrf2 的作用。
- 批准号:
7694970 - 财政年份:2008
- 资助金额:
$ 11.08万 - 项目类别:
Prevention of UVB-induced skin cancer using sulforaphane: roles of AP-1 and Nrf2.
使用萝卜硫素预防 UVB 诱发的皮肤癌:AP-1 和 Nrf2 的作用。
- 批准号:
7922622 - 财政年份:2008
- 资助金额:
$ 11.08万 - 项目类别:
相似海外基金
A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis
一项 2 期、随机、双盲、4 组、多中心研究,旨在证明处方药局部剂量制剂治疗光化性角化病的有效性和安全性
- 批准号:
10820810 - 财政年份:2023
- 资助金额:
$ 11.08万 - 项目类别:
Investigational new drug enabling studies for the development of a topical fixed dose combination drug product to treat actinic keratosis and prevent cutaneous squamous cell carcinoma.
研究性新药使研究能够开发局部固定剂量组合药物产品,以治疗光化性角化病和预防皮肤鳞状细胞癌。
- 批准号:
10482509 - 财政年份:2022
- 资助金额:
$ 11.08万 - 项目类别:
Skin Cancer Risks and Risk Prediction in Patients with Actinic Keratosis
光化性角化病患者的皮肤癌风险和风险预测
- 批准号:
10448977 - 财政年份:2022
- 资助金额:
$ 11.08万 - 项目类别:
Skin Cancer Risks and Risk Prediction in Patients with Actinic Keratosis
光化性角化病患者的皮肤癌风险和风险预测
- 批准号:
10610895 - 财政年份:2022
- 资助金额:
$ 11.08万 - 项目类别:
Investigational new drug enabling studies for the development of a topical fixed dose combination drug product to treat actinic keratosis and prevent cutaneous squamous cell carcinoma.
研究性新药使研究能够开发局部固定剂量组合药物产品,以治疗光化性角化病和预防皮肤鳞状细胞癌。
- 批准号:
10701001 - 财政年份:2022
- 资助金额:
$ 11.08万 - 项目类别:
MTAK - Microwave Therapy for Actinic Keratosis
MTAK - 光化性角化病的微波疗法
- 批准号:
103352 - 财政年份:2017
- 资助金额:
$ 11.08万 - 项目类别:
Collaborative R&D
From actinic keratosis to invasive squamous cell carcinoma: Impact of AHR and p27KIP1 on malignant transformation
从光化性角化病到浸润性鳞状细胞癌:AHR 和 p27KIP1 对恶性转化的影响
- 批准号:
511942584 - 财政年份:
- 资助金额:
$ 11.08万 - 项目类别:
Research Units
PHARMACOLOGY OF VITAMIN A IN PATIENTS WITH ACTINIC KERATOSIS
维生素 A 在光化性角化病患者中的药理学
- 批准号:
4691509 - 财政年份:
- 资助金额:
$ 11.08万 - 项目类别:
PHARMACOLOGY OF VITAMIN A IN PATIENTS WITH ACTINIC KERATOSIS
维生素 A 在光化性角化病患者中的药理学
- 批准号:
3962586 - 财政年份:
- 资助金额:
$ 11.08万 - 项目类别:














{{item.name}}会员




